U.S. Markets open in 6 hrs 58 mins
  • S&P Futures

    3,600.75
    +24.75 (+0.69%)
     
  • Dow Futures

    29,778.00
    +232.00 (+0.79%)
     
  • Nasdaq Futures

    11,971.00
    +65.75 (+0.55%)
     
  • Russell 2000 Futures

    1,837.50
    +20.40 (+1.12%)
     
  • Crude Oil

    43.56
    +0.50 (+1.16%)
     
  • Gold

    1,828.50
    -9.30 (-0.51%)
     
  • Silver

    23.50
    -0.14 (-0.58%)
     
  • EUR/USD

    1.1857
    +0.0011 (+0.0949%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3348
    +0.0026 (+0.1922%)
     
  • USD/JPY

    104.4400
    -0.0480 (-0.0459%)
     
  • BTC-USD

    18,416.68
    +84.17 (+0.46%)
     
  • CMC Crypto 200

    369.38
    +7.95 (+2.20%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)?

Simply Wall St
·5 min read

A look at the shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

Intra-Cellular Therapies isn't enormous, but it's not particularly small either. It has a market capitalization of US$2.1b, which means it would generally expect to see some institutions on the share registry. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Intra-Cellular Therapies.

See our latest analysis for Intra-Cellular Therapies

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Intra-Cellular Therapies?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Intra-Cellular Therapies. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Intra-Cellular Therapies' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Intra-Cellular Therapies is not owned by hedge funds. FMR LLC is currently the largest shareholder, with 13% of shares outstanding. The Vanguard Group, Inc. is the second largest shareholder owning 7.8% of common stock, and BlackRock, Inc. holds about 7.4% of the company stock. Furthermore, CEO Sharon Mates is the owner of 1.8% of the company's shares.

On further inspection, we found that more than half the company's shares are owned by the top 8 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Intra-Cellular Therapies

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Intra-Cellular Therapies, Inc.. This is a big company, so it is good to see this level of alignment. Insiders own US$107m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 13% stake in Intra-Cellular Therapies. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 6.9%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 4 warning signs for Intra-Cellular Therapies you should know about.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.